The AHRQ review may underrepresent the evidence base for prolonged grief disorder (PGD), impacting clinical care.
Interpersonal psychotherapy for PGD shows a 71% response rate, significantly higher than the 44% for citalopram.
The AHRQ review's grouping of heterogeneous psychotherapy studies may dilute the effectiveness signals for PGD-specific interventions.
PGD is recognized in DSM-5-TR and has validated diagnostic tools and effective therapies demonstrated in randomized trials.
Digital grief interventions show promise, but scalability and implementation challenges remain for PGD treatment.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Editor
Affiliations:
Specialties:
Areas of Expertise:
